Does the media prefer VERA or ACRS?

In the previous week, Aclaris Therapeutics had 2 more articles in the media than Vera Therapeutics. MarketBeat recorded 3 mentions for Aclaris Therapeutics and 1 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.07 beat Aclaris Therapeutics' score of 0.76 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ACRS or IRON?

In the previous week, Disc Medicine had 4 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 7 mentions for Disc Medicine and 3 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.76 beat Disc Medicine's score of 0.58 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Disc Medicine 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MOR or ACRS?

Aclaris Therapeutics has a consensus price target of $11.50, indicating a potential upside of 106.46%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aclaris Therapeutics is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aclaris Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.13

Does the media favor ACRS or MBX?

In the previous week, MBX Biosciences had 1 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 4 mentions for MBX Biosciences and 3 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.76 beat MBX Biosciences' score of 0.24 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ACRS or QURE?

In the previous week, Aclaris Therapeutics had 2 more articles in the media than uniQure. MarketBeat recorded 3 mentions for Aclaris Therapeutics and 1 mentions for uniQure. Aclaris Therapeutics' average media sentiment score of 0.76 beat uniQure's score of 0.72 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aclaris Therapeutics (ACRS) Competitors

$5.57 -0.11 (-1.94%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$5.63 +0.06 (+1.10%)

As of 07/20/2026 07:57 PM Eastern

Compare

ACRS vs. VERA, IRON, MOR, MBX, and QURE

Should you buy Aclaris Therapeutics stock or one of its competitors? MarketBeat compares Aclaris Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aclaris Therapeutics include Vera Therapeutics (VERA), Disc Medicine (IRON), MorphoSys (MOR), MBX Biosciences (MBX), and uniQure (QURE). These companies are all part of the "pharmaceutical products" industry.

How does Aclaris Therapeutics compare to Vera Therapeutics?

Vera Therapeutics (NASDAQ:VERA) and Aclaris Therapeutics (NASDAQ:ACRS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

Aclaris Therapeutics has higher revenue and earnings than Vera Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A
Aclaris Therapeutics	$7.83M	99.35	-$64.92M	-$0.56	N/A

Vera Therapeutics has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Aclaris Therapeutics' return on equity of -55.89% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-74.86%	-60.18%
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

Vera Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

Vera Therapeutics presently has a consensus price target of $84.58, suggesting a potential upside of 128.67%. Aclaris Therapeutics has a consensus price target of $11.50, suggesting a potential upside of 106.46%. Given Vera Therapeutics' higher possible upside, equities research analysts plainly believe Vera Therapeutics is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 15.9% of Vera Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Aclaris Therapeutics had 2 more articles in the media than Vera Therapeutics. MarketBeat recorded 3 mentions for Aclaris Therapeutics and 1 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.07 beat Aclaris Therapeutics' score of 0.76 indicating that Vera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclaris Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vera Therapeutics and Aclaris Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Aclaris Therapeutics compare to Disc Medicine?

Aclaris Therapeutics (NASDAQ:ACRS) and Disc Medicine (NASDAQ:IRON) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Aclaris Therapeutics currently has a consensus price target of $11.50, indicating a potential upside of 106.46%. Disc Medicine has a consensus price target of $104.44, indicating a potential upside of 40.42%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aclaris Therapeutics is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Disc Medicine had 4 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 7 mentions for Disc Medicine and 3 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.76 beat Disc Medicine's score of 0.58 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Disc Medicine	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 83.7% of Disc Medicine shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Disc Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aclaris Therapeutics has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Disc Medicine has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Disc Medicine's return on equity of -36.94% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
Disc Medicine	N/A	-36.94%	-33.88%

Aclaris Therapeutics has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	99.35	-$64.92M	-$0.56	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A

Summary

Aclaris Therapeutics beats Disc Medicine on 10 of the 16 factors compared between the two stocks.

How does Aclaris Therapeutics compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Aclaris Therapeutics (NASDAQ:ACRS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Aclaris Therapeutics has a consensus price target of $11.50, indicating a potential upside of 106.46%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aclaris Therapeutics is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

MorphoSys has a net margin of -226.79% compared to Aclaris Therapeutics' net margin of -832.58%. Aclaris Therapeutics' return on equity of -55.89% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

In the previous week, Aclaris Therapeutics had 3 more articles in the media than MorphoSys. MarketBeat recorded 3 mentions for Aclaris Therapeutics and 0 mentions for MorphoSys. Aclaris Therapeutics' average media sentiment score of 0.76 beat MorphoSys' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
MorphoSys	Neutral
Aclaris Therapeutics	Positive

18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Aclaris Therapeutics has lower revenue, but higher earnings than MorphoSys. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Aclaris Therapeutics	$7.83M	99.35	-$64.92M	-$0.56	N/A

Summary

Aclaris Therapeutics beats MorphoSys on 12 of the 17 factors compared between the two stocks.

How does Aclaris Therapeutics compare to MBX Biosciences?

Aclaris Therapeutics (NASDAQ:ACRS) and MBX Biosciences (NASDAQ:MBX) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

Aclaris Therapeutics presently has a consensus target price of $11.50, suggesting a potential upside of 106.46%. MBX Biosciences has a consensus target price of $63.00, suggesting a potential upside of 4.76%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Aclaris Therapeutics is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Aclaris Therapeutics has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	99.35	-$64.92M	-$0.56	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A

Aclaris Therapeutics has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market.

MBX Biosciences has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. MBX Biosciences' return on equity of -24.52% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
MBX Biosciences	N/A	-24.52%	-23.59%

In the previous week, MBX Biosciences had 1 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 4 mentions for MBX Biosciences and 3 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.76 beat MBX Biosciences' score of 0.24 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.3% of Aclaris Therapeutics shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 31.1% of MBX Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Aclaris Therapeutics beats MBX Biosciences on 10 of the 16 factors compared between the two stocks.

How does Aclaris Therapeutics compare to uniQure?

Aclaris Therapeutics (NASDAQ:ACRS) and uniQure (NASDAQ:QURE) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Aclaris Therapeutics has a net margin of -832.58% compared to uniQure's net margin of -1,154.42%. Aclaris Therapeutics' return on equity of -55.89% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
uniQure	-1,154.42%	-145.81%	-27.15%

In the previous week, Aclaris Therapeutics had 2 more articles in the media than uniQure. MarketBeat recorded 3 mentions for Aclaris Therapeutics and 1 mentions for uniQure. Aclaris Therapeutics' average media sentiment score of 0.76 beat uniQure's score of 0.72 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aclaris Therapeutics has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, uniQure has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

Aclaris Therapeutics has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	99.35	-$64.92M	-$0.56	N/A
uniQure	$16.10M	155.52	-$198.97M	-$3.48	N/A

Aclaris Therapeutics presently has a consensus price target of $11.50, suggesting a potential upside of 106.46%. uniQure has a consensus price target of $64.17, suggesting a potential upside of 61.63%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Aclaris Therapeutics is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
uniQure	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by insiders. Comparatively, 4.7% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Aclaris Therapeutics beats uniQure on 12 of the 17 factors compared between the two stocks.

Get Aclaris Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACRS vs. The Competition

Export

Metric	Aclaris Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$793.29M	$3.07B	$6.89B	$12.28B
Dividend Yield	N/A	2.05%	2.67%	9.39%
P/E Ratio	-9.95	20.20	27.06	23.94
Price / Sales	99.35	340.68	517.51	91.94
Price / Cash	N/A	27.11	26.68	47.25
Price / Book	6.55	4.20	10.66	6.14
Net Income	-$64.92M	$65.94M	$3.60B	$331.74M
7 Day Performance	2.58%	-3.05%	-1.23%	-1.81%
1 Month Performance	23.78%	-1.30%	1.10%	-1.44%
1 Year Performance	239.63%	15.22%	23.65%	16.33%

Aclaris Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACRS Aclaris Therapeutics	2.786 of 5 stars	$5.57 -1.9%	$11.50 +106.5%	+246.0%	$793.29M	$7.83M	N/A	100	News Coverage
VERA Vera Therapeutics	3.5618 of 5 stars	$41.50 -1.2%	$84.58 +103.8%	+60.5%	$2.98B	N/A	N/A	40
IRON Disc Medicine	2.5453 of 5 stars	$75.98 -0.8%	$104.44 +37.5%	+28.8%	$2.90B	N/A	N/A	30
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
MBX MBX Biosciences	1.2549 of 5 stars	$59.97 -1.8%	$60.22 +0.4%	N/A	$2.85B	N/A	N/A	N/A	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACRS) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aclaris Therapeutics (ACRS) Competitors

ACRS vs. VERA, IRON, MOR, MBX, and QURE

How does Aclaris Therapeutics compare to Vera Therapeutics?

Summary

How does Aclaris Therapeutics compare to Disc Medicine?

Summary

How does Aclaris Therapeutics compare to MorphoSys?

Summary

How does Aclaris Therapeutics compare to MBX Biosciences?

Summary

How does Aclaris Therapeutics compare to uniQure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRS vs. The Competition

Aclaris Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aclaris Therapeutics (ACRS) Competitors

ACRS vs. VERA, IRON, MOR, MBX, and QURE

How does Aclaris Therapeutics compare to Vera Therapeutics?

Which has preferable valuation and earnings, VERA or ACRS?

Is VERA or ACRS more profitable?

Which has more volatility & risk, VERA or ACRS?

Do analysts prefer VERA or ACRS?

Do insiders & institutionals hold more shares of VERA or ACRS?

Does the media prefer VERA or ACRS?

Summary

How does Aclaris Therapeutics compare to Disc Medicine?

Do analysts recommend ACRS or IRON?

Does the media favor ACRS or IRON?

Do insiders & institutionals have more ownership in ACRS or IRON?

Which has more volatility and risk, ACRS or IRON?

Is ACRS or IRON more profitable?

Which has higher valuation and earnings, ACRS or IRON?

Summary

How does Aclaris Therapeutics compare to MorphoSys?

Do analysts rate MOR or ACRS?

Is MOR or ACRS more profitable?

Which has more risk and volatility, MOR or ACRS?

Does the media refer more to MOR or ACRS?

Do insiders and institutionals believe in MOR or ACRS?

Which has better valuation & earnings, MOR or ACRS?

Summary

How does Aclaris Therapeutics compare to MBX Biosciences?

Do analysts rate ACRS or MBX?

Which has stronger valuation & earnings, ACRS or MBX?

Which has more risk & volatility, ACRS or MBX?

Is ACRS or MBX more profitable?

Does the media favor ACRS or MBX?

Do insiders & institutionals hold more shares of ACRS or MBX?

Summary

How does Aclaris Therapeutics compare to uniQure?

Is ACRS or QURE more profitable?

Does the media prefer ACRS or QURE?

Which has more risk & volatility, ACRS or QURE?

Which has better earnings & valuation, ACRS or QURE?

Do analysts recommend ACRS or QURE?

Do insiders and institutionals hold more shares of ACRS or QURE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRS vs. The Competition

Aclaris Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools